Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS-B: Vutrisiran in Transthyretin Amyloidosis with Cardiomyopathy
2019-003153-28Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) and amyloid cardiomyopathy comparing Vutrisiran with Placebo (2 arms). Primary endpoint: Composite outcome of all-cause mortality and recurrent cardiovascular hospitalizations. Started Nov 2019; status: completed.
02
Drugs
vutrisiran
03
Conditions
transthyretin amyloidosis (ATTR)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2019-003153-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003153-28.